Dept. of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, Univ. of South Carolina, Columbia, SC 29208, USA.
Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15;304(2):R155-63. doi: 10.1152/ajpregu.00363.2012. Epub 2012 Nov 21.
Overactive bladder (OAB) is often associated with increased involuntary detrusor smooth muscle (DSM) contractions during the bladder-filling phase. To develop novel therapies for OAB, it is critical to better understand the mechanisms that control DSM excitability and contractility. Recent studies showed that small-conductance Ca(2+)-activated K(+) (SK) channels, SK3 channels, in particular, regulate human DSM function. However, the concept that SK channel-selective pharmacological activation can decrease the excitability and contractility directly in human DSM needs further exploration. Here, we studied the effect of the novel and potent SK channel activator, SKA-31 (or naphtho [1,2-d]thiazol-2-ylamine), on human DSM excitability and contractility at the cellular and tissue level. We used isometric tension recordings on human DSM-isolated strips and the perforated patch-clamp technique on freshly isolated native human DSM cells. SKA-31 significantly decreased spontaneous phasic contractions of DSM-isolated strips. In the presence of the SK channel blocker, apamin, the inhibitory effects of SKA-31 on the DSM spontaneous phasic contractions were significantly reduced. SKA-31 decreased the carbachol- and KCl-induced contractions in human DSM strips. Electrical field stimulation-induced contractions were significantly attenuated in the presence of SKA-31 at all stimulation frequencies (0.5-50 Hz). SKA-31 hyperpolarized the resting membrane potential of human DSM cells. Apamin abolished the hyperpolarizing effect of SKA-31, indicating the involvement of SK channel activation. These results support the concept that pharmacological activation of SK channels with selective openers may represent an attractive new pharmacological approach for decreasing DSM excitability and contractility, thus controlling OAB.
膀胱过度活动症(OAB)常伴有膀胱充盈期逼尿肌不自主收缩增加。为了开发治疗 OAB 的新疗法,深入了解控制逼尿肌兴奋性和收缩性的机制至关重要。最近的研究表明,小电导钙激活钾(SK)通道,尤其是 SK3 通道,调节人类逼尿肌功能。然而,SK 通道选择性药理学激活可直接降低人类逼尿肌兴奋性和收缩性的概念仍需要进一步探索。在这里,我们在细胞和组织水平上研究了新型强效 SK 通道激活剂 SKA-31(或萘并[1,2-d]噻唑-2-基胺)对人逼尿肌兴奋性和收缩性的影响。我们使用人逼尿肌分离条的等长张力记录和新鲜分离的天然人逼尿肌细胞的穿孔膜片钳技术。SKA-31 显著降低了逼尿肌分离条的自发性相收缩。在 SK 通道阻断剂阿帕米的存在下,SKA-31 对逼尿肌自发性相收缩的抑制作用显著降低。SKA-31 降低了人逼尿肌条中乙酰胆碱和氯化钾诱导的收缩。在所有刺激频率(0.5-50 Hz)下,SKA-31 存在时,电刺激诱导的收缩明显减弱。SKA-31 使人类逼尿肌细胞的静息膜电位超极化。阿帕米消除了 SKA-31 的超极化作用,表明 SK 通道的激活参与其中。这些结果支持这样的概念,即选择性开放剂的 SK 通道药理学激活可能代表一种有吸引力的新药理学方法,可降低逼尿肌兴奋性和收缩性,从而控制 OAB。